
    
      This is a double-blind, randomised, placebo-controlled, parallel group study. Subjects will
      undertake a screening period which may last up to approximately 3 weeks, followed by a
      baseline period of 1 week, a randomised treatment period of 5 weeks and a follow-up period of
      approximately 2 weeks.

      This is a multi-centre, double-blind, randomised, placebo-controlled study in subjects who
      have at least moderate intensity of neuropathic pain resulting from lumbosacral
      radiculipathy. It will investigate the efficacy, safety and tolerability of GW856553.

      Approximately 142 subjects will be randomised to ensure 128 evaluable subjects. Randomisation
      ratio will be 1:1 for placebo or GW856553 respectively. The dose of GW856553 will be 7.5 mg
      BID.
    
  